Cargando…
Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma
BACKGROUND: Xenobiotic Metabolizing Enzymes (XMEs) contribute to the detoxification of numerous cancer therapy-induced products. This study investigated the susceptibility and prognostic implications of the CYP2E1, CYP2C19, CYP2D6, mEH and NAT2 gene polymorphisms in breast carcinoma patients. METHOD...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377277/ https://www.ncbi.nlm.nih.gov/pubmed/18423013 http://dx.doi.org/10.1186/1471-2407-8-109 |
_version_ | 1782154806814572544 |
---|---|
author | Khedhaier, Achraf Hassen, Elham Bouaouina, Noureddine Gabbouj, Sallouha Ahmed, Slim Ben Chouchane, Lotfi |
author_facet | Khedhaier, Achraf Hassen, Elham Bouaouina, Noureddine Gabbouj, Sallouha Ahmed, Slim Ben Chouchane, Lotfi |
author_sort | Khedhaier, Achraf |
collection | PubMed |
description | BACKGROUND: Xenobiotic Metabolizing Enzymes (XMEs) contribute to the detoxification of numerous cancer therapy-induced products. This study investigated the susceptibility and prognostic implications of the CYP2E1, CYP2C19, CYP2D6, mEH and NAT2 gene polymorphisms in breast carcinoma patients. METHODS: The authors used polymerase chain reaction and restriction enzyme digestion to characterize the variation of the CYP2E1, CYP2C19, CYP2D6, mEH and NAT2 gene in a total of 560 unrelated subjects (246 controls and 314 patients). RESULTS: The mEH (C/C) mutant and the NAT2 slow acetylator genotypes were significantly associated with breast carcinoma risk (p = 0.02; p = 0.01, respectively). For NAT2 the association was more pronounced among postmenopausal patients (p = 0.006). A significant association was found between CYP2D6 (G/G) wild type and breast carcinoma risk only in postmenopausal patients (p = 0.04). Association studies of genetic markers with the rates of breast carcinoma specific overall survival (OVS) and the disease-free survival (DFS) revealed among all breast carcinoma patients no association to DFS but significant differences in OVS only with the mEH gene polymorphisms (p = 0.02). In addition, the mEH wild genotype showed a significant association with decreased OVS in patients with axillary lymph node-negative patients (p = 0.03) and with decreasesd DFS in patients with axillary lymph node-positive patients (p = 0.001). However, the NAT2 intermediate acetylator genotype was associated with decreased DFS in axillary lymph node-negative patients. CONCLUSION: The present study may prove that polymorphisms of some XME genes may predict the onset of breast carcinoma as well as survival after treatment. |
format | Text |
id | pubmed-2377277 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-23772772008-05-13 Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma Khedhaier, Achraf Hassen, Elham Bouaouina, Noureddine Gabbouj, Sallouha Ahmed, Slim Ben Chouchane, Lotfi BMC Cancer Research Article BACKGROUND: Xenobiotic Metabolizing Enzymes (XMEs) contribute to the detoxification of numerous cancer therapy-induced products. This study investigated the susceptibility and prognostic implications of the CYP2E1, CYP2C19, CYP2D6, mEH and NAT2 gene polymorphisms in breast carcinoma patients. METHODS: The authors used polymerase chain reaction and restriction enzyme digestion to characterize the variation of the CYP2E1, CYP2C19, CYP2D6, mEH and NAT2 gene in a total of 560 unrelated subjects (246 controls and 314 patients). RESULTS: The mEH (C/C) mutant and the NAT2 slow acetylator genotypes were significantly associated with breast carcinoma risk (p = 0.02; p = 0.01, respectively). For NAT2 the association was more pronounced among postmenopausal patients (p = 0.006). A significant association was found between CYP2D6 (G/G) wild type and breast carcinoma risk only in postmenopausal patients (p = 0.04). Association studies of genetic markers with the rates of breast carcinoma specific overall survival (OVS) and the disease-free survival (DFS) revealed among all breast carcinoma patients no association to DFS but significant differences in OVS only with the mEH gene polymorphisms (p = 0.02). In addition, the mEH wild genotype showed a significant association with decreased OVS in patients with axillary lymph node-negative patients (p = 0.03) and with decreasesd DFS in patients with axillary lymph node-positive patients (p = 0.001). However, the NAT2 intermediate acetylator genotype was associated with decreased DFS in axillary lymph node-negative patients. CONCLUSION: The present study may prove that polymorphisms of some XME genes may predict the onset of breast carcinoma as well as survival after treatment. BioMed Central 2008-04-18 /pmc/articles/PMC2377277/ /pubmed/18423013 http://dx.doi.org/10.1186/1471-2407-8-109 Text en Copyright © 2008 Khedhaier et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Khedhaier, Achraf Hassen, Elham Bouaouina, Noureddine Gabbouj, Sallouha Ahmed, Slim Ben Chouchane, Lotfi Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma |
title | Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma |
title_full | Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma |
title_fullStr | Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma |
title_full_unstemmed | Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma |
title_short | Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma |
title_sort | implication of xenobiotic metabolizing enzyme gene (cyp2e1, cyp2c19, cyp2d6, meh and nat2) polymorphisms in breast carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377277/ https://www.ncbi.nlm.nih.gov/pubmed/18423013 http://dx.doi.org/10.1186/1471-2407-8-109 |
work_keys_str_mv | AT khedhaierachraf implicationofxenobioticmetabolizingenzymegenecyp2e1cyp2c19cyp2d6mehandnat2polymorphismsinbreastcarcinoma AT hassenelham implicationofxenobioticmetabolizingenzymegenecyp2e1cyp2c19cyp2d6mehandnat2polymorphismsinbreastcarcinoma AT bouaouinanoureddine implicationofxenobioticmetabolizingenzymegenecyp2e1cyp2c19cyp2d6mehandnat2polymorphismsinbreastcarcinoma AT gabboujsallouha implicationofxenobioticmetabolizingenzymegenecyp2e1cyp2c19cyp2d6mehandnat2polymorphismsinbreastcarcinoma AT ahmedslimben implicationofxenobioticmetabolizingenzymegenecyp2e1cyp2c19cyp2d6mehandnat2polymorphismsinbreastcarcinoma AT chouchanelotfi implicationofxenobioticmetabolizingenzymegenecyp2e1cyp2c19cyp2d6mehandnat2polymorphismsinbreastcarcinoma |